{
    "organizations": [],
    "uuid": "11961b5d990887cc070e87fac09b02493700be6c",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/02/globe-newswire-novavax-to-host-conference-call-to-discuss-first-quarter-financial-results-on-may-9-2018.html",
    "ord_in_thread": 0,
    "title": "Novavax to Host Conference Call to Discuss Financial on May 9,",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "GAITHERSBURG, Md., May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.\nConference call details are as follows:\nDate: May 9, 2018 Time: 4:30 p.m. U.S. Eastern Time (ET) Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International) Passcode: 3687883 Webcast: www.novavax.com , “Investors”/ “Events”\nConference call and webcast replay:\nDates: Starting at 7:30 p.m. ET, May 9, 2018 until 7:30 p.m. ET May 16, 2018 Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International) Passcode: 3687883 Webcast: www.novavax.com , “Investors”/ “Events”, until August 9, 2017\nAbout Novavax\nNovavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com .\nContact:\nInvestors\nErika Trahan\nSenior Manager, Investor & Public Relations\nir@novavax.com\n240-268-2000\nWestwicke Partners\nJohn Woolford\njohn.woolford@westwicke.com\n443-213-0506\nMedia\nSam Brown\nMike Beyer\nmikebeyer@sambrown.com\n312-961-2502\nSource:Novavax, Inc.",
    "published": "2018-05-03T00:05:00.000+03:00",
    "crawled": "2018-05-03T01:59:14.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "gaithersburg",
        "may",
        "globe",
        "newswire",
        "novavax",
        "nasdaq",
        "nvax",
        "today",
        "announced",
        "report",
        "first",
        "operating",
        "result",
        "following",
        "close",
        "financial",
        "market",
        "wednesday",
        "may",
        "conference",
        "call",
        "detail",
        "follows",
        "date",
        "may",
        "time",
        "eastern",
        "time",
        "et",
        "number",
        "domestic",
        "international",
        "passcode",
        "webcast",
        "investor",
        "event",
        "conference",
        "call",
        "webcast",
        "replay",
        "date",
        "starting",
        "et",
        "may",
        "et",
        "may",
        "number",
        "domestic",
        "international",
        "passcode",
        "webcast",
        "investor",
        "event",
        "august",
        "novavax",
        "novavax",
        "nasdaq",
        "nvax",
        "biotechnology",
        "company",
        "committed",
        "delivering",
        "novel",
        "product",
        "prevent",
        "infectious",
        "disease",
        "rsv",
        "influenza",
        "nanoparticle",
        "vaccine",
        "candidate",
        "novavax",
        "advanced",
        "clinical",
        "program",
        "forefront",
        "novavax",
        "effort",
        "improve",
        "global",
        "health",
        "information",
        "please",
        "visit",
        "contact",
        "investor",
        "erika",
        "trahan",
        "senior",
        "manager",
        "investor",
        "public",
        "relation",
        "ir",
        "westwicke",
        "partner",
        "john",
        "woolford",
        "medium",
        "sam",
        "brown",
        "mike",
        "beyer",
        "mikebeyer",
        "source",
        "novavax",
        "inc"
    ]
}